NTRK1 and neoplasm: Given the poor outlook for patients with advanced cervical cancer and the central role played by receptor tyrosine kinases in tumour proliferation and angiogenesis, it would therefore be rational to test a novel, multi-targeted inhibitor of angiogenesis in patients with unresectable, locally advanced or metastatic cervical carcinoma.